OnKure Therapeutics, Inc. (OKUR)
NGM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
OnKure proposes increasing equity shares and electing directors at annual meeting
# 📜 What This Document Is 📢 This document is a **Proxy Statement (DEF 14A)**. Think of it as a detailed instruction manual mailed to stockholders before a big vote. It explains *why* the company needs you to vote and *what* specific proposals you will be voting on. The filing is for OnKure Thera
SEC filings
All filings →Insider trades
All insider trades →OnKure Therapeutics, Inc. has no reported insider trades in the last 90 days.